These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31039059)

  • 21. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
    Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
    J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
    Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
    Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does race predict survival for women with invasive breast cancer?
    Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
    Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Closing the Gap: Identifying Rates and Reasons for Nonadherence in a Specialty Population.
    Paolella D; Cherry E; Jolly JA; DeClercq J; Choi L; Zuckerman A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1282-1288. PubMed ID: 31663457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
    Haskins CB; Neuner JM; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
    Clin Breast Cancer; 2020 Jun; 20(3):e261-e280. PubMed ID: 32139273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Influencing Adherence to Adjuvant Endocrine Therapy After Breast Cancer Surgery.
    Johnsson A; von Wachenfeldt A
    Cancer Rep (Hoboken); 2024 Aug; 7(8):e2160. PubMed ID: 39158164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.
    Farias AJ; Wu WH; Du XL
    Med Oncol; 2018 Jun; 35(7):113. PubMed ID: 29926275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System.
    Hui RL; Adams AL; Niu F; Ettinger B; Yi DK; Chandra M; Lo JC
    J Manag Care Spec Pharm; 2017 Apr; 23(4):503-512. PubMed ID: 28345435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to adjuvant endocrine therapy among White British and ethnic minority breast cancer survivors in the United Kingdom.
    McGuinness S; Hughes L; Moss-Morris R; Hunter M; Norton S; Moon Z
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13722. PubMed ID: 36255032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
    Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Influence of a Community Pharmacy Automatic Prescription Refill Program on Medicare Part D Adherence Metrics.
    Lester CA; Mott DA; Chui MA
    J Manag Care Spec Pharm; 2016 Jul; 22(7):801-7. PubMed ID: 27348281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
    Sheppard VB; Dash C; Nomura S; Sutton AL; Franco RL; Lucas A; Ross M; Adams-Campbell L
    Cancer; 2020 Sep; 126(17):4059-4066. PubMed ID: 32614992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-reported adherence and reasons for nonadherence among patients with low proportion of days covered for antihypertension medications.
    Kharmats AY; Martinez TR; Belli H; Zhao Y; Mann DM; Schoenthaler AM; Voils CI; Blecker S
    J Manag Care Spec Pharm; 2023 May; 29(5):557-563. PubMed ID: 37121253
    [No Abstract]   [Full Text] [Related]  

  • 35. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
    Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
    BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
    Farias AJ; Du XL
    Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
    [No Abstract]   [Full Text] [Related]  

  • 38. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD; Shewale AR; Talbert JC
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
    Farias AJ; Du XL
    Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.